Johnson & Johnson (JNJ)
Salud / Farmacéutica y tecnología médica
The largest diversified healthcare company (Innovative Medicine + MedTech), with 63 consecutive years of dividend increases, that has already recovered much of the decline from its 52-week low to ~$273: trading at ~24× adjusted earnings, reasonably valued — Preserves value, with the talc litigation and the Darzalex patent expiration (2029) as the risks that cap the upside.
- Price
- $273.02
- Intrinsic value (5y, base)
- $249
- Total annual return (5y)
- 0.5%
- Status (nominal)
- Preserves value
- Margin of safety
- No margin
The essentials
- The largest diversified healthcare company: Innovative Medicine (~64% of revenue — oncology, immunology, neuroscience) + MedTech (~36% — cardiovascular, orthopaedics, surgery, vision). 63 consecutive years of dividend increases; investment-grade rating from Moody's and S&P (level not specified in the filing).
- GAAP earnings ($26.8bn FY2025) are inflated by the ~$7.0bn reversal of the talc reserve after the bankruptcy plan was rejected in March 2025 → valued on adjusted earnings ($10.79 FY2025, guidance ~$11.55 in 2026), with the oncology pipeline (Darzalex +23.0%, Carvykti +95.9%) and immunology (Tremfya +40.5%) offsetting the decline in Stelara (−41.3%, from biosimilars).
- It has already recovered much of the decline from its 52-week low toward ~$273: at ~24× adjusted earnings (vs ~16-17× historical) → Preserves value. Talc litigation (~74,360 plaintiffs as of Dec-2025) and the Darzalex patent expiration (2029, 15.0% of revenue) cap the upside. The return is dividend (2.0%) + growing earnings − multiple reversion.
Intrinsic value — two valuation methods
Total return at 5 years: 0.5%/year = -1.8% appreciation + 2.4% dividend. The target price ($249) is ex-dividend; the $31 in dividends collected over 5 years are added separately.
The methods disagree: one places the value today above the price ($273) and the other below.
Pillars of the analysis
The verdict — today vs 5 years
Today — expensive, no margin of safety: at $273 trades ~20.3% above its value discounted to today (~$227); the expected return does not even reach the risk-free rate (4.5%).
At 5 years — Preserva valor: the target price ($249) plus dividends yield just enough to preserve nominal capital, below the required 4% floor.
The bridge: the return at 5 years falls below the risk-free rate (4.5%) — which is why there is not even a discount to today's value. To require a 15% annual return, it would need to be bought at ~$144.
Thesis
The business
J&J is a defensive quality compounder: the largest diversified healthcare company, with an investment-grade rating (Moody's and S&P), 63 consecutive years of dividend increases, and a moat of patents + research and development scale + diversification between Innovative Medicine and MedTech. Its growth is moderate (consolidated revenue +6.0% in 2025), limited by the cadence of patent expirations (Stelara already, Darzalex in 2029) and the expansion of Medicare price setting, but reasonably predictable. It is not a broken or disrupted business; it is a mature franchise with known, disclosed risks.
The valuation
It is valued on P/E over adjusted earnings, not GAAP: FY2025 GAAP earnings ($26.8bn, EPS $11.03) are inflated by a ~$7.0bn non-cash reversal of the talc reserve (after the Texas bankruptcy plan was rejected in March 2025) — the clean metric is adjusted earnings ($10.79 FY2025, guidance ~$11.55 in 2026). Net income delivers the equity directly (net debt is $27.8bn at FY2025 year-end, modest relative to market value, and lives in the DCF).
The base scenario projects a value of ~$249 per share over five years, an annual return of ~+1% from the current ~$273. The key: the stock has already recovered much of the decline from its 52-week low toward ~$273 → trading at ~24× adjusted earnings, above its historical norm of ~16-17×. As earnings grow and the multiple reverts toward the norm (~19×), the price stays roughly flat; the return comes largely from the dividend (2.0%).
The margin of safety
The verdict is Preserves value: No margin of safety: at this price capital is preserved, but it is not bought below its value.. The stock's recovery from its 52-week low closed much of the discount: at ~$273 J&J trades at a premium to its ~16-17× historical norm for a moderately growing business. The expected return (~+1%) is growing earnings plus the dividend (2.0%, 63 consecutive years of increases) minus multiple reversion. The margin of safety is limited at this price — the quality is recognized by the market; the talc litigation and the Darzalex patent expiration (2029) are the offsetting risks that justify not paying a higher premium.
What to watch
The central disconfirmer: does the oncology pipeline (Darzalex, Carvykti, Tremfya, the bispecifics) replace the patent expirations — Stelara already, Darzalex in 2029 with 15.0% of revenue — without adjusted earnings stalling? The signals: Innovative Medicine growth excluding Stelara, pipeline data, and the margin against the expansion of Medicare price setting (Erleada enters the selected list starting 2028). And the talc litigation: the ovarian cancer trials scheduled throughout 2026 in the court system, the securities class action — with class certification confirmed by the Third Circuit in July 2025 and a petition for certiorari filed with the Supreme Court in February 2026, still unresolved —, and whether the final exposure exceeds the $3.4bn reserved.
Educational / informational. Does not constitute investment advice.